Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Renovel Innovations Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being reviewed by 1 distinct examiner in 1 distinct art unit, reflecting a concentrated prosecution effort for the company's current filings. This indicates that the active portfolio is currently limited to a single technical application or a very specific area within the biotechnology sector.
The busiest examiner, SEAMAN, D MARGARET M, is responsible for 1 busiest examiner pending office action. This means the company's current active portfolio is entirely under the review of this single examiner, which can streamline the communication and strategy for the practitioner. Because there is only 1 distinct examiner and 1 pending office action, there is no need to coordinate across different art units or manage multiple reviewer personalities.
In the Biotechnology & Pharmaceuticals field, having only 1 distinct examiner involved allows for a very direct prosecution strategy. With 1 pending office action total, the workload is minimal, and the practitioner can focus entirely on the specific concerns of SEAMAN, D MARGARET M. This singular focus on 1 busiest examiner pending office action provides a clear and uncomplicated path for resolving the company's current patent matters at the office.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SEAMAN, D MARGARET M | 1 | 76.6% | +8.1% |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18942833 | HALOGENATED BENZYLIDINE DERIVATIVES | SEAMAN, D MARGARET M | 1625 | §102DP | Non-Final OA | — | Pending | Nov 11, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRenovel Innovations Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
D Margaret M Seaman has the most, with 1 of Renovel Innovations Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
